Life-style and metformin for the prevention of endometrial pathology in postmenopausal women

Gynecological Endocrinology

Volumn 29, Issue 2, 2013, Pages 119-124

  Campagnoli, Carlo ^a   Abbà, Chiara ^a   Ambroggio, Simona ^a   Brucato, Tiziana ^a   Pasanisi, Patrizia ^b  

^a Ospedale Ginecologico Sant Anna   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Endometrial cancer; Endometrial hyperplasia; Insulin; Metformin; Sex hormones

Indexed keywords

ANDROGEN; ESTROGEN; INSULIN; METFORMIN;

ARTICLE; CALORIC RESTRICTION; CANCER PREVENTION; CANCER RISK; DISEASE ASSOCIATION; DISEASE DURATION; DRUG EFFECT; ENDOMETRIAL DISEASE; ENDOMETRIUM CARCINOMA; ENDOMETRIUM HYPERPLASIA; FEMALE; HORMONE BLOOD LEVEL; HUMAN; HYPERINSULINEMIA; INSULIN RESISTANCE; LIFESTYLE MODIFICATION; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PHYSICAL ACTIVITY; POSTMENOPAUSE; PRIORITY JOURNAL; PROPHYLAXIS; RISK FACTOR; RISK REDUCTION; SEDENTARY LIFESTYLE; TREATMENT INDICATION; WEIGHT REDUCTION;

ANTICARCINOGENIC AGENTS; CARCINOMA, ENDOMETRIOID; ENDOMETRIAL NEOPLASMS; ENDOMETRIUM; EVIDENCE-BASED MEDICINE; FEMALE; HUMANS; HYPERPLASIA; LIFE STYLE; METFORMIN; POSTMENOPAUSE; PROTECTIVE AGENTS; RISK FACTORS; UTERINE DISEASES;

EID: 84871435086     PISSN: 09513590     EISSN: 14730766     Source Type: Journal    
DOI: 10.3109/09513590.2012.706671     Document Type: Article

References (70)

1. World Cancer Research Fund, American Institute for Cancer Research. Food, nutrition, physical activity and the prevention of cancer: a global perspective. Washington, DC: AICR; 2007.
2. Haenszel W, Kurihara M. Studies of Japanese migrants. I. Mortality from cancer and other diseases among Japanese in the United States. J Natl Cancer Inst 1968;40:43-68.
3. Gadducci A, Gargini A, Palla E, Fanucchi A, Genazzani AR. Polycystic ovary syndrome and gynecological cancers: is there a link? Gynecol Endocrinol 2005;20:200-208. (Pubitemid 40862906)
4. Kaaks R, Lukanova A, Kurzer MS. Obesity, endogenous hormones, and endometrial cancer risk: a synthetic review. Cancer Epidemiol Biomarkers Prev 2002;11:1531-1543. (Pubitemid 36020003)
5. Gallagher EJ, LeRoith D. Diabetes, cancer, and metformin: connections of metabolism and cell proliferation. Ann N Y Acad Sci 2011;1243:54-68.
6. Goodwin PJ, Stambolic V, Lemieux J, Chen BE, Parulekar WR, Gelmon KA, Hershman DL, et al. Evaluation of metformin in early breast cancer: a modification of the traditional paradigm for clinical testing of anti-cancer agents. Breast Cancer Res Treat 2011;126:215-220.
7. Sivridis E, Giatromanolaki A. The pathogenesis of endometrial carcinomas at menopause: facts and figures. J Clin Pathol 2011;64:553-560.
8. Lacey JV Jr, Chia VM. Endometrial hyperplasia and the risk of progression to carcinoma. Maturitas 2009;63:39-44.
9. Pasqualini JR, Chetrite GS. Recent advances on the action of estrogens and progestogens in normal and pathological human endometrium. Horm Mol Biol Clin Invest 2010;2:155-175.
10. Epplein M, Reed SD, Voigt LF, Newton KM, Holt VL, Weiss NS. Risk of complex and atypical endometrial hyperplasia in relation to anthropometric measures and reproductive history. Am J Epidemiol 2008;168:563-70; discussion 571.
11. Kreiger N, Marrett LD, Clarke EA, Hilditch S, Woolever CA. Risk factors for adenomatous endometrial hyperplasia: a case-control study. Am J Epidemiol 1986;123:291-301. (Pubitemid 16158551)
12. Ricci E, Moroni S, Parazzini F, Surace M, Benzi G, Salerio B, Polverino G, La Vecchia C. Risk factors for endometrial hyperplasia: results from a case-control study. Int J Gynecol Cancer 2002;12:257-260. (Pubitemid 34787552)
13. Bray F, Dos Santos Silva I, Moller H, Weiderpass E. Endometrial cancer incidence trends in Europe: underlying determinants and prospects for prevention. Cancer Epidemiol Biomarkers Prev 2005;14:1132-1142. (Pubitemid 40656458)
14. Byers T, Sedjo RL. Does intentional weight loss reduce cancer risk? Diabetes Obes Metab 2011;13:1063-1072.
15. Vigneri P, Frasca F, Sciacca L, Pandini G, Vigneri R. Diabetes and cancer. Endocr Relat Cancer 2009;16:1103-1123.
16. Moore SC, Gierach GL, Schatzkin A, Matthews CE. Physical activity, sedentary behaviours, and the prevention of endometrial cancer. Br J Cancer 2010;103:933-938.
17. Conroy MB, Sattelmair JR, Cook NR, Manson JE, Buring JE, Lee IM. Physical activity, adiposity, and risk of endometrial cancer. Cancer Causes Control 2009;20:1107-1115.
18. Friberg E, Mantzoros CS, Wolk A. Physical activity and risk of endometrial cancer: a population-based prospective cohort study. Cancer Epidemiol Biomarkers Prev 2006;15:2136-2140. (Pubitemid 44877037)
19. Friedenreich C, Cust A, Lahmann PH, Steindorf K, Boutron-Ruault MC, Clavel-Chapelon F, Mesrine S, et al. Physical activity and risk of endometrial cancer: the European prospective investigation into cancer and nutrition. Int J Cancer 2007;121:347-355. (Pubitemid 46917704)
20. Gierach GL, Chang SC, Brinton LA, Lacey JV Jr, Hollenbeck AR, Schatzkin A, Leitzmann MF. Physical activity, sedentary behavior, and endometrial cancer risk in the NIH-AARP Diet and Health Study. Int J Cancer 2009;124:2139-2147.
21. Patel AV, Feigelson HS, Talbot JT, McCullough ML, Rodriguez C, Patel RC, Thun MJ, Calle EE. The role of body weight in the relationship between physical activity and endometrial cancer: results from a large cohort of US women. Int J Cancer 2008;123:1877-1882.
22. Friedenreich CM, Neilson HK, Lynch BM. State of the epidemiological evidence on physical activity and cancer prevention. Eur J Cancer 2010;46:2593-2604.
23. Simpson ER, Misso M, Hewitt KN, Hill RA, Boon WC, Jones ME, Kovacic A, et al. Estrogen-the good, the bad, and the unexpected. Endocr Rev 2005;26:322-330.
24. Labrie F, Martel C, Balser J. Wide distribution of the serum dehydroepiandrosterone and sex steroid levels in postmenopausal women: role of the ovary? Menopause 2011;18:30-43.
25. Blouin K, Nadeau M, Mailloux J, Daris M, Lebel S, Luu-The V, Tchernof A. Pathways of adipose tissue androgen metabolism in women: depot differences and modulation by adipogenesis. Am J Physiol Endocrinol Metab 2009;296:E244-E255.
26. Purohit A, Woo LW, Potter BV. Steroid sulfatase: a pivotal player in estrogen synthesis and metabolism. Mol Cell Endocrinol 2011;340:154-160.
27. Cappola AR, Ratcliffe SJ, Bhasin S, Blackman MR, Cauley J, Robbins J, Zmuda JM, et al. Determinants of serum total and free testosterone levels in women over the age of 65 years. J Clin Endocrinol Metab 2007;92:509-516.
28. Danforth KN, Eliassen AH, Tworoger SS, Missmer SA, Barbieri RL, Rosner BA, Colditz GA, Hankinson SE. The association of plasma androgen levels with breast, ovarian and endometrial cancer risk factors among postmenopausal women. Int J Cancer 2010;126:199-207.
29. Fogle RH, Stanczyk FZ, Zhang X, Paulson RJ. Ovarian androgen production in postmenopausal women. J Clin Endocrinol Metab 2007;92:3040-3043. (Pubitemid 47236368)
30. Key TJ, Appleby PN, Reeves GK, Roddam AW, Helzlsouer KJ, Alberg AJ, Rollison DE, et al.; Endogenous Hormones and Breast Cancer Collaborative Group. Circulating sex hormones and breast cancer risk factors in postmenopausal women: reanalysis of 13 studies. Br J Cancer 2011;105:709-722.
31. Zang H, Sahlin L, Masironi B, Eriksson E, Lind Hirschberg A. Effects of testosterone treatment on endometrial proliferation in postmenopausal women. J Clin Endocrinol Metab 2007;92:2169-2175. (Pubitemid 46997117)
32. Audet-Walsh E, Line J, Groire J, Plante M, Caron P, Tu B, Ayotte P, et al. Profiling of endogenous estrogens, their precursors, and metabolites in endometrial cancer patients: association with risk and relationship to clinical characteristics. J Clin Endocrinol Metab 2011;96:E330-E339.
33. Allen NE, Key TJ, Dossus L, Rinaldi S, Cust A, Lukanova A, Peeters PH, et al. Endogenous sex hormones and endometrial cancer risk in women in the European Prospective Investigation into Cancer and Nutrition (EPIC). Endocr Relat Cancer 2008;15:485-497. (Pubitemid 351880837)
34. Lukanova A, Lundin E, Micheli A, Arslan A, Ferrari P, Rinaldi S, Krogh V, et al. Circulating levels of sex steroid hormones and risk of endometrial cancer in postmenopausal women. Int J Cancer 2004;108:425-432. (Pubitemid 37549609)
35. Effects of hormone replacement therapy on endometrial histology in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial. JAMA 1996;275:370-375.
36. Agorastos T, Vaitsi V, Pantazis K, Efstathiadis E, Vavilis D, Bontis JN. Aromatase inhibitor anastrozole for treating endometrial hyperplasia in obese postmenopausal women. Eur J Obstet Gynecol Reprod Biol 2005;118:239-240. (Pubitemid 40093842)
37. Cushing KL, Weiss NS, Voigt LF, McKnight B, Beresford SA. Risk of endometrial cancer in relation to use of low-dose, unopposed estrogens. Obstet Gynecol 1998;91:35-39. (Pubitemid 28042329)
38. Gunter MJ, Hoover DR, Yu H, Wassertheil-Smoller S, Manson JE, Li J, Harris TG, et al. A prospective evaluation of insulin and insulinlike growth factor-I as risk factors for endometrial cancer. Cancer Epidemiol Biomarkers Prev 2008;17:921-929. (Pubitemid 351536424)
39. Wang T, Rohan TE, Gunter MJ, Xue X, Wactawski-Wende J, Rajpathak SN, Cushman M, et al. A prospective study of inflammation markers and endometrial cancer risk in postmenopausal hormone nonusers. Cancer Epidemiol Biomarkers Prev 2011;20:971-977.
40. Barone BB, Yeh HC, Snyder CF, Peairs KS, Stein KB, Derr RL, Wolff AC, Brancati FL. Long-term all-cause mortality in cancer patients with preexisting diabetes mellitus: a systematic review and meta-analysis. JAMA 2008;300:2754-2764.
41. Rubin GL, Peterson HB, Lee NC, Maes EF, Wingo PA, Becker S. Estrogen replacement therapy and the risk of endometrial cancer: remaining controversies. Am J Obstet Gynecol 1990;162:148-154. (Pubitemid 20055439)
42. Burzawa JK, Schmeler KM, Soliman PT, Meyer LA, Bevers MW, Pustilnik TL, Anderson ML, et al. Prospective evaluation of insulin resistance among endometrial cancer patients. Am J Obstet Gynecol 2011;204:355.e1-355.e7.
43. Cust AE, Kaaks R, Friedenreich C, Bonnet F, Laville M, Tjneland A, Olsen A, et al. Metabolic syndrome, plasma lipid, lipoprotein and glucose levels, and endometrial cancer risk in the European Prospective Investigation into Cancer and Nutrition (EPIC). Endocr Relat Cancer 2007;14:755-767. (Pubitemid 350074064)
44. Rosato V, Zucchetto A, Bosetti C, Dal Maso L, Montella M, Pelucchi C, Negri E, et al. Metabolic syndrome and endometrial cancer risk. Ann Oncol 2011;22:884-889.
45. Maturana MA, Spritzer PM. Association between hyperinsulinemia and endogenous androgen levels in peri-and postmenopausal women. Metab Clin Exp 2002;51:238-243. (Pubitemid 34168239)
46. Patel SM, Ratcliffe SJ, Reilly MP, Weinstein R, Bhasin S, Blackman MR, Cauley JA, et al. Higher serum testosterone concentration in older women is associated with insulin resistance, metabolic syndrome, and cardiovascular disease. J Clin Endocrinol Metab 2009;94:4776-4784.
47. Palomba S, Falbo A, Zullo F, Orio F Jr. Evidence-based and potential benefits of metformin in the polycystic ovary syndrome: a comprehensive review. Endocr Rev 2009;30:1-50.
48. Nagamani M, Stuart CA. Specific binding and growth-promoting activity of insulin in endometrial cancer cells in culture. Am J Obstet Gynecol 1998;179:6-12. (Pubitemid 28394466)
49. Sheets EE, Tsibris JC, Cook NI, Virgin SD, DeMay RM, Spellacy WN. In vitro binding of insulin and epidermal growth factor to human endometrium and endocervix. Am J Obstet Gynecol 1985;153:60-65. (Pubitemid 15240766)
50. McCampbell AS, Broaddus RR, Walker CL. Loss of inhibitory insulin receptor substrate-1 phosphorylation: An early event in endometrial hyperplasia and progression to carcinoma. Cell Cycle 2010;9:2698-2699.
51. Becker S, Dossus L, Kaaks R. Obesity related hyperinsulinaemia and hyperglycaemia and cancer development. Arch Physiol Biochem 2009;115:86-96.
52. Moon HS, Chamberland JP, Aronis K, Tseleni-Balafouta S, Mantzoros CS. Direct role of adiponectin and adiponectin receptors in endometrial cancer: in vitro and ex vivo studies in humans. Mol Cancer Ther 2011;10:2234-2243.
53. Hooper LE, Foster-Schubert KE, Weigle DS, Sorensen B, Ulrich CM, McTiernan A. Frequent intentional weight loss is associated with higher ghrelin and lower glucose and androgen levels in postmenopausal women. Nutr Res 2010;30:163-170.
54. Schmandt RE, Iglesias DA, Co NN, Lu KH. Understanding obesity and endometrial cancer risk: opportunities for prevention. Am J Obstet Gynecol 2011;205:518-525.
55. Giovannucci E, Harlan DM, Archer MC, Bergenstal RM, Gapstur SM, Habel LA, Pollak M, et al. Diabetes and cancer: a consensus report. CA Cancer J Clin 2010;60:207-221.
56. Hawley JA, Lessard SJ. Exercise training-induced improvements in insulin action. Acta Physiol (Oxf) 2008;192:127-135. (Pubitemid 350265363)
57. Ligibel JA, Campbell N, Partridge A, Chen WY, Salinardi T, Chen H, Adloff K, et al. Impact of a mixed strength and endurance exercise intervention on insulin levels in breast cancer survivors. J Clin Oncol 2008;26:907-912. (Pubitemid 351398083)
58. Liedtke S, Schmidt ME, Becker S, Kaaks R, Zaineddin AK, Buck K, Flesch-Janys D, et al. Physical activity and endogenous sex hormones in postmenopausal women: to what extent are observed associations confounded or modified by BMI? Cancer Causes Control 2011;22:81-89.
59. van Gils CH, Peeters PH, Schoenmakers MC, Nijmeijer RM, Onland-Moret NC, van der Schouw YT, Monninkhof EM. Physical activity and endogenous sex hormone levels in postmenopausal women: a cross-sectional study in the Prospect-EPIC Cohort. Cancer Epidemiol Biomarkers Prev 2009;18:377-383.
60. Bertone-Johnson ER, Tworoger SS, Hankinson SE. Recreational physical activity and steroid hormone levels in postmenopausal women. Am J Epidemiol 2009;170:1095-1104.
61. Cust AE. Physical activity and gynecologic cancer prevention. Recent Results Cancer Res 2011;186:159-185.
62. Kuller LH. Metformin use among individuals at risk for type 2 diabetes. Curr Diab Rep 2012;12:265-273.
63. McCormack J, Johns K, Tildesley H. Metformin's contraindications should be contraindicated. CMAJ 2005;173:502-504. (Pubitemid 41225045)
64. Decensi A, Puntoni M, Goodwin P, Cazzaniga M, Gennari A, Bonanni B, Gandini S. Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis. Cancer Prev Res (Phila) 2010;3:1451-1461.
65. Currie CJ, Poole CD, Jenkins-Jones S, Gale EA, Johnson JA, Morgan CL. Mortality after incident cancer in people with and without type 2 diabetes: impact of metformin on survival. Diabetes Care 2012;35:299-304.
66. Patel SM, Iqbal N, Kaul S, Ratcliffe SJ, Rickels MR, Reilly MP, Scattergood T, et al. Effects of metformin and leuprolide acetate on insulin resistance and testosterone levels in nondiabetic postmenopausal women: a randomized, placebo-controlled trial. Fertil Steril 2010;94:2161-2166.
67. Campagnoli C, Pasanisi P, Abb C, Ambroggio S, Biglia N, Brucato T, Colombero R, et al. Effect of different doses of metformin on serum testosterone and insulin in non-diabetic women with breast cancer: a randomized study. Clin Breast Cancer 2012;12:175-182.
68. Brown KA, Hunger NI, Docanto M, Simpson ER. Metformin inhibits aromatase expression in human breast adipose stromal cells via stimulation of AMP-activated protein kinase. Breast Cancer Res Treat 2010;123:591-596.
69. Cantrell LA, Zhou C, Mendivil A, Malloy KM, Gehrig PA, Bae-Jump VL. Metformin is a potent inhibitor of endometrial cancer cell proliferation- implications for a novel treatment strategy. Gynecol Oncol 2010;116:92-98.
70. Tan BK, Adya R, Chen J, Lehnert H, Sant Cassia LJ, Randeva HS. Metformin treatment exerts antiinvasive and antimetastatic effects in human endometrial carcinoma cells. J Clin Endocrinol Metab 2011;96:808-816.